Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335903 | 0.93 | CA2 (0.53) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL6846544 | 0.89 | CA2 (0.46) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL249395 | 0.86 | CA2 (0.46) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL7879155 | 0.86 | CA2 (0.49) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL6846304 | 0.85 | CA2 (0.50) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL3747655 | 0.82 | MMP8 (0.38) | CA2CA1MAPK1MMP8 | |
| SCHEMBL11051590 | 0.79 | CA2 (0.58) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL20299539 | 0.78 | CA2 (0.56) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL2049913 | 0.77 | CA2 (0.51) | CA2CA1MAPK1ATML3MBTL1 | |
| SCHEMBL8729030 | 0.77 | CA2 (0.51) | CA2CA1MAPK1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1071662-B1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | AKZO NOBEL NV (NL) | 2004-08-04 | — | — | EP | disclosed |
| US-6770774-B2 | USING A PEROXY COMPOUND AS CURING AGENT, POLYMERIZATION CATALYST | AKZO NOBEL N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030073861-A1 | Using a peroxy compound as curing agent, polymerization catalyst | VAN DE BOVENKAMP-BOUWMAN ANNA (NL) | 2003-04-17 | — | — | US | disclosed |
| US-6482970-B1 | Peroxides, their preparation process and use | AKZO NOBEL NV (NL) | 2002-11-19 | — | — | US | disclosed |
| EP-1071662-A1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | Akzo Nobel N.V. (NL) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999052864-A1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | AKZO NOBEL N.V. (NL) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073861-A1 | Using a peroxy compound as curing agent, polymerization catalyst | PRDX4, ACOX3, PRDX2 | CA2 270/4885CA1 248/4885MAPK1 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.